BioLineRx and Compugen partnered to develop peptide drug candidates discovered by Compugen to treat chronic inflammatory diseases, cardiac diseases, retinopathy and cancer

Compugen Ltd.

Israel / Small-Cap Biopharma (<$1 billion)

$161.6m on 12/16/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

BioLineRx Ltd.

Israel / Small-Cap Biopharma (<$1 billion)

$40.4m on 12/16/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced